 |
  
|
  |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
Medical News Schering-Plough Drug Gets Fast TrackJanuary 31, 2006 Schering-Plough said Monday that the Food and Drug Administration had given fast track status to its experimental hepatitis C drug SCH 503034. The medication is now in mid-stage human trials as an oral treatment for chronic hepatitis C infection. Fast track status allows the manufacturer to submit data as they become available, instead of all at once, and it gives a formal framework for discussions with FDA during the review period. The target patients for the new drug, FDA said, are those with a specific hepatitis C genotype 1 strain who have failed on standard treatments. Associated Press 01.30.06  This article was provided by U.S. Centers for Disease Control and Prevention. It is a part of the publication CDC HIV/Hepatitis/STD/TB Prevention News Update.
|
 |
Email
Print-Friendly
Glossary
The Body: About The Body | Contact The Body | Content Policy | Content Providers | Advertise With Us | Site Map
Remedy Health Media: About Remedy Health Media | Contact Remedy Health Media | Terms of Use | Privacy Policy
The Body is a service of Remedy Health Media, LLC, 250 West 57th Street, New York, NY 10107. The Body and its logos are trademarks of Remedy Health Media, LLC, and its subsidiaries, which owns the copyright of The Body's homepage, topic pages, page designs and HTML code. General Disclaimer: The Body is designed for educational purposes only and is not engaged in rendering medical advice or professional services. The information provided through The Body should not be used for diagnosing or treating a health problem or a disease. It is not a substitute for professional care. If you have or suspect you may have a health problem, consult your health care provider.
